Harmony Biosciences Holdings (HRMY)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|
Gross profit | US$ in thousands | 460,786 | 354,374 | 249,922 | 132,004 |
Revenue | US$ in thousands | 548,499 | 419,060 | 255,101 | 134,691 |
Gross profit margin | 84.01% | 84.56% | 97.97% | 98.01% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $460,786K ÷ $548,499K
= 84.01%
Harmony Biosciences Holdings Inc has exhibited a declining trend in its gross profit margin over the past four years. The gross profit margin decreased from 82.64% in 2020 to 79.17% in 2023. This indicates a decrease in the percentage of revenue retained after accounting for the cost of goods sold. A lower gross profit margin may suggest challenges in managing production costs or pricing strategies. Further investigation into the company's cost structure and pricing policies may be warranted to understand the reasons behind this downward trend and to identify potential areas for improvement.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Harmony Biosciences Holdings
HRMY
84.01%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
39.97%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%